Seizure Disorders: Classification, Antiseizure Medication Selection, and Status Epilepticus

A seizure is a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Epilepsy is defined as a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures, typically requiring at least two unprovoked seizures occurring more than 24 hours apart.

[KEY_CONCEPT] The International League Against Epilepsy (ILAE) classification system categorizes seizures based on three key features: onset (focal vs. generalized vs. unknown), awareness (retained vs. impaired), and motor features (motor vs. non-motor).

Seizure Classification Framework

Status Epilepticus (SE) represents a medical emergency defined as continuous seizure activity or recurrent seizures without recovery of consciousness lasting ≥5 minutes for convulsive SE or ≥10 minutes for focal SE with impaired consciousness [1].

[HIGH_YIELD] Acute symptomatic seizures occur within 1 week of an acute CNS insult (stroke, trauma, infection), while remote symptomatic seizures occur after the acute phase and represent epilepsy [4]. The distinction is crucial for treatment duration decisions.

[CLINICAL_PEARL] Post-stroke epilepsy affects 2-4% of stroke survivors, with higher risk in hemorrhagic strokes, cortical involvement, and severe strokes. Early seizures (within 7 days) do not necessarily predict epilepsy development [6].

Clinical assessment of seizure disorders requires detailed history-taking, witness accounts, and careful neurological examination. The diagnostic approach must distinguish epileptic seizures from seizure mimics and classify seizure types accurately.

Diagnostic Criteria for Epilepsy

Epilepsy is diagnosed when ANY of the following conditions are met:

• ☑ At least 2 unprovoked seizures occurring >24 hours apart
• ☑ One unprovoked seizure and probability of further seizures >60% over next 10 years
• ☑ Diagnosis of an epilepsy syndrome

[KEY_CONCEPT] Electroencephalography (EEG) is essential for seizure classification and epilepsy syndrome identification. Routine EEG captures seizures in <5% of patients, while continuous EEG monitoring is required for nonconvulsive status epilepticus diagnosis [1].

Key History Elements

Pre-ictal Phase:

• Aura or warning signs
• Precipitating factors (sleep deprivation, stress, flashing lights)
• Medication adherence

Ictal Phase:

• Level of consciousness
• Motor phenomena (tonic, clonic, myoclonic)
• Automatisms (lip smacking, picking movements)
• Lateralizing signs (head/eye deviation, unilateral motor activity)
• Duration and evolution

Post-ictal Phase:

• Confusion duration
• Focal deficits (Todd's paralysis)
• Tongue biting, incontinence

[HIGH_YIELD] Red flags requiring emergent evaluation include:

• First seizure in adult >40 years
• Focal neurological deficits
• Fever or signs of infection
• History of head trauma
• Prolonged post-ictal confusion

Differential Diagnosis of Seizure-like Events

[CLINICAL_PEARL] Serum prolactin levels drawn 15-20 minutes post-ictally may help distinguish generalized tonic-clonic seizures from psychogenic events, but sensitivity is limited and should not be used as the sole diagnostic criterion.

Antiseizure medication (ASM) selection requires consideration of seizure type, patient factors, side effect profile, and drug interactions. The goal is seizure freedom with minimal adverse effects.

First-Line ASM Selection by Seizure Type

[KEY_CONCEPT] Mechanism of action understanding guides rational polytherapy:

• Sodium channel blockers: Carbamazepine, lamotrigine, phenytoin
• GABA enhancers: Valproate, benzodiazepines, vigabatrin
• Calcium channel modulators: Gabapentin, pregabalin
• Synaptic vesicle protein modulators: Levetiracetam, brivaracetam

ASM Treatment Algorithm

Seizure Diagnosis Confirmed ↓ Determine Seizure Type/Syndrome ↓ Select Appropriate First-Line ASM ↓ Start Low, Titrate Slowly to Effective Dose ↓ Seizure Control Achieved? → YES → Continue Monitoring ↓ NO Optimize Dose (Check Levels if Indicated) ↓ Still Inadequate Control? ↓ ADD Second ASM (Different Mechanism) → Gradual Cross-Titration if Necessary ↓ Refractory Epilepsy (Failed 2 Appropriate ASMs) ↓ Consider:

• Epilepsy Surgery Evaluation
• VNS/RNS/DBS
• Dietary Therapy
• Clinical Trials

[HIGH_YIELD] Special populations require modified approaches:

Women of childbearing potential [3]:

• Avoid valproate due to teratogenic risk
• Folic acid supplementation 0.4-4mg daily
• Lamotrigine requires dose adjustments during pregnancy
• Breastfeeding generally safe with most ASMs

Elderly patients:

• Start with lower doses
• Consider drug interactions
• Monitor for cognitive effects
• Preferred: lamotrigine, levetiracetam

[CLINICAL_PEARL] Acute symptomatic seizures typically require short-term ASM treatment (days to weeks) rather than chronic therapy, depending on the underlying etiology and risk of recurrence [4]. Post-stroke seizures may warrant 3-6 months of treatment if late-onset.

Therapeutic drug monitoring is indicated for:

• Phenytoin, carbamazepine, valproate (routine)
• Suspected non-adherence
• Drug interactions
• Pregnancy
• Breakthrough seizures despite adequate dosing

Status Epilepticus (SE) is a neurological emergency requiring immediate intervention. Early recognition and treatment are critical for preventing neuronal injury and reducing morbidity and mortality [1].

Status Epilepticus Classification

Convulsive SE:

• Generalized convulsive (tonic-clonic)
• Focal motor with impaired awareness
• Time points: 5 minutes = treatment threshold; 30 minutes = refractory SE

Non-convulsive SE:

• Absence SE
• Focal SE with impaired awareness
• Diagnosis requires continuous EEG monitoring [1]

Emergency Treatment Protocol

STATUS EPILEPTICUS SUSPECTED (≥5 minutes continuous seizure) ↓ 0-5 MINUTES: IMMEDIATE STABILIZATION

• ABC assessment (Airway, Breathing, Circulation)
• IV access, O2, glucose, thiamine
• Lorazepam 0.1 mg/kg IV (max 4 mg) OR
• Midazolam 10 mg IM/IN OR
• Diazepam 0.15 mg/kg IV (max 10 mg) ↓ SEIZURE CONTINUES? ↓ 5-20 MINUTES: SECOND-LINE THERAPY Choose ONE:
• Fosphenytoin 20 mg PE/kg IV (preferred)
• Phenytoin 20 mg/kg IV
• Valproate 40 mg/kg IV
• Levetiracetam 60 mg/kg IV (max 4.5 g) ↓ SEIZURE CONTINUES? (REFRACTORY SE) ↓ 20-40 MINUTES: THIRD-LINE THERAPY
• Anesthesia consultation
• Continuous EEG monitoring
• ICU admission [1] Choose ONE:
• Midazolam 0.2 mg/kg IV bolus, then 0.05-2 mg/kg/h
• Propofol 1-2 mg/kg IV bolus, then 2-10 mg/kg/h
• Pentobarbital 5-15 mg/kg IV bolus, then 0.5-5 mg/kg/h

[HIGH_YIELD] Key management principles:

• Time is critical: Benzodiazepines most effective within first 10-20 minutes
• Avoid delays: Don't wait for IV access - use IM/intranasal routes
• EEG monitoring: Essential for non-convulsive SE diagnosis [1]
• Underlying causes: Address precipitants (infection, metabolic, structural)

Common SE Etiologies

[CLINICAL_PEARL] Refractory SE (failure to respond to first and second-line therapy) occurs in 23-43% of cases and requires aggressive ICU management with continuous anesthetic agents and EEG monitoring [1].

Complications of SE:

• Hyperthermia, hypoxia, aspiration
• Rhabdomyolysis, acute kidney injury
• Cardiac arrhythmias, hypotension
• Neuronal injury (excitotoxicity)

[KEY_CONCEPT] Super-refractory SE persists despite 24+ hours of anesthetic treatment and may require consideration of:

• Ketogenic diet
• Immunotherapy
• Hypothermia
• Novel agents (perampanel, cannabidiol)

Long-term management of epilepsy requires ongoing monitoring for seizure control, medication adherence, adverse effects, and psychosocial factors. Regular follow-up is essential for optimizing outcomes.

Monitoring Parameters

Clinical Monitoring:

• Seizure frequency and type (seizure diary)
• Medication adherence assessment
• Adverse effects screening
• Quality of life measures
• Driving restrictions compliance

Laboratory Monitoring:

• Baseline: CBC, CMP, LFTs
• ASM-specific monitoring (levels when indicated)
• Periodic: Vitamin D, bone density (enzyme-inducing ASMs)

[HIGH_YIELD] Drug interactions are particularly important with enzyme-inducing ASMs (carbamazepine, phenytoin, phenobarbital):

• Reduced efficacy: Oral contraceptives, warfarin, immunosuppressants
• Increased metabolism: Other ASMs, resulting in subtherapeutic levels

Pregnancy Considerations [3]

Pre-conception counseling:

• Optimize seizure control with lowest effective dose
• Switch from valproate if possible
• Folic acid supplementation 0.4-4 mg daily
• Genetic counseling for inherited epilepsy syndromes

During pregnancy:

• Monthly ASM levels (especially lamotrigine)
• Increased clearance may require dose adjustments
• Continue ASM therapy - seizure risks outweigh medication risks
• High-resolution ultrasound at 18-22 weeks

Major congenital malformation rates [3]:

• General population: 2-3%
• Lamotrigine monotherapy: 2-3%
• Levetiracetam monotherapy: 2-3%
• Valproate monotherapy: 6-11%
• Polytherapy: Higher risk

When to Consider Epilepsy Surgery

Criteria for surgical evaluation:

• Drug-resistant epilepsy (failed ≥2 appropriate ASMs)
• Identifiable epileptogenic focus
• Seizures significantly impair quality of life
• Favorable risk-benefit ratio

Surgical options:

• Resective surgery: Temporal lobectomy, lesionectomy
• Disconnective surgery: Corpus callosotomy, hemispherectomy
• Neuromodulation: VNS, RNS, DBS

[CLINICAL_PEARL] Seizure freedom rates after temporal lobectomy range from 60-80% at 2 years, making surgery a viable option for carefully selected patients with mesial temporal sclerosis.

Prognosis and Long-term Outcomes

Factors affecting prognosis:

• Favorable: Idiopathic generalized epilepsy, early seizure control
• Unfavorable: Structural etiology, frequent seizures, cognitive impairment

Seizure remission rates:

• 60-70% achieve seizure freedom with first ASM
• Additional 10-15% controlled with second ASM
• 20-30% develop drug-resistant epilepsy

[KEY_CONCEPT] SUDEP (Sudden Unexpected Death in Epilepsy) risk factors include:

• Frequent generalized tonic-clonic seizures
• Young age at onset
• Long epilepsy duration
• Subtherapeutic ASM levels
• Risk reduction through seizure control optimization